简报:真实世界中伊匹木单抗联合纳武利尤单抗治疗胸膜间皮瘤的毒性与生存——RIOMeso研究
RIOMeso回顾性收集澳大利亚11个中心119例接受伊匹木单抗联合纳武利尤单抗治疗的胸膜间皮瘤患者资料,评估真实世界生存与毒性。全队列中位总生存14.5个月(95%CI 13.0-未达到),24%发生≥3级不良事件,包括3例治疗相关死亡。作者认为真实世界生存结局较临床试验差且似乎毒性更大。
要点
- 全队列中位总生存14.5个月(95%CI 13.0-未达到),一线治疗者亦为14.5个月(95%CI 12.5-未达到)。
- 24%患者发生≥3级不良事件,包括3例治疗相关死亡,结肠炎为最常见不良事件。
- 上皮样型中位总生存19.1个月vs非上皮样型13.0个月,差异未达统计学显著(p=0.064)。
核心结论
- 真实世界中伊匹木单抗联合纳武利尤单抗治疗胸膜间皮瘤的生存结局较临床试验数据更差,且似乎毒性更大。
研究设计与样本
- RIOMeso为回顾性研究,收集澳大利亚11个中心119例接受伊匹木单抗联合纳武利尤单抗一线及后线治疗胸膜间皮瘤患者的人口学与临床病理资料。
主要发现
- 全队列中位年龄72岁,83%为男性,92%东部肿瘤协作组评分≤1,50%为既往或当前吸烟者,78%有已知石棉暴露。
- 组织学类型:上皮样50%、肉瘤样19%、双相型14%、17%不可获得;75%患者为一线使用伊匹木单抗联合纳武利尤单抗。
- 全队列中位总生存14.5个月(95%CI 13.0-未达到);一线治疗者14.5个月(95%CI 12.5-未达到),二线或后线治疗者15.4个月(95%CI 11.2-未达到)。
- 上皮样型中位总生存19.1个月(95%CI 15.4-未达到)vs非上皮样型13.0个月(95%CI 9.7-未达到),p=0.064,差异未达统计学显著。
- 24%患者发生常见不良事件评价标准第5.0版≥3级不良事件,包括3例治疗相关死亡;结肠炎为最常见不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Australia has one of the highest rates of asbestos-associated diseases. Mesothelioma remains an area of unmet need with a 5-year overall survival of 10%. First-line immunotherapy with ipilimumab and nivolumab is now a standard of care for unresectable pleural mesothelioma following the CheckMate 743 trial, with supportive data from the later line single-arm MAPS2 trial. RIOMeso evaluates survival and toxicity of this regimen in real-world practice. METHODS: Demographic and clinicopathologic data of Australian patients treated with ipilimumab and nivolumab in first- and subsequent-line settings for pleural mesothelioma were collected retrospectively. Survival was reported using the Kaplan-Meier method and compared between subgroups with the log-rank test. Toxicity was investigator assessed using Common Terminology Criteria for Adverse Events version 5.0. RESULTS: A total of 119 patients were identified from 11 centers. The median age was 72 years, 83% were male, 92% had Eastern Cooperative Oncology Group less than or equal to 1, 50% were past or current smokers, and 78% had known asbestos exposure. In addition, 50% were epithelioid, 19% sarcomatoid, 14% biphasic, and 17% unavailable. Ipilimumab and nivolumab were used first line in 75% of patients. Median overall survival (mOS) was 14.5 months (95% confidence interval [CI]: 13.0-not reached [NR]) for the entire cohort. For patients treated first line, mOS was 14.5 months (95% CI: 12.5-NR) and in second- or later-line patients was 15.4 months (95% CI: 11.2-NR). There was no statistically significant difference in mOS for epithelioid patients compared with nonepithelioid (19.1 mo [95% CI: 15.4-NR] versus 13.0 mo [95% CI: 9.7-NR], respectively, p = 0.064). Furthermore, 24% of the patients had a Common Terminology Criteria for Adverse Events grade greater than or equal to 3 adverse events, including three treatment-related deaths. Colitis was the most frequent adverse event. CONCLUSIONS: Combination immunotherapy in real-world practice has poorer survival outcomes and seems more toxic compared with clinical trial data. This is the first detailed report of real-world survival and toxicity outcomes using ipilimumab and nivolumab treatment of pleural mesothelioma.
引用
- McNamee N, Harvey C, Gray L, et al. Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso. J Thorac Oncol. 2023. PMID: 38036250. doi:10.1016/j.jtho.2023.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。